ARTICLE | Company News
Exact up on Cologuard reimbursement
October 11, 2014 2:05 AM UTC
Exact Sciences Corp. (NASDAQ:EXAS) jumped $6.48 (36%) to $24.60 on Friday, adding $537.4 million in market cap to $2 billion, on news CMS has proposed reimbursement of $502 for Cologuard, the company's non-invasive DNA screening test for colorectal cancer.
CMS on Thursday issued its final National Coverage Determination (NCD) for Cologuard, which establishes national coverage for the test once every three years for asymptomatic beneficiaries aged 50-85 who are at average risk of developing colorectal cancer. ...